Open Access iconOpen Access

ARTICLE

PRPF6 promotes metastasis and paclitaxel resistance of ovarian cancer via SNHG16/CEBPB/GATA3 axis

HAN WANG, YINGYING ZHOU, SIYANG ZHANG, YA QI, MIN WANG*

Department of Gynecology and Obstetrics, Shengjing Hospital of China Medical University, Shenyang, China

* Corresponding Author: MIN WANG. Email: email

Oncology Research 2021, 29(4), 275-289. https://doi.org/10.32604/or.2022.03561

Abstract

Metastasis and paclitaxel (PTX) resistance are the main reason for the poor prognosis of ovarian cancer (OC). Evidence showed that RNA-binding proteins (RBPs) and long noncoding RNAs (lncRNAs) can modulate post-transcriptional regulation. The aim of this study was to determine the relationship among RBP, lncRNA and OC and to further guide clinical therapy. Immunohistochemistry revealed that pre-mRNA processing factor 6 (PRPF6) was upregulated in OC chemoresistant tissues and was closely related to advanced (Federation of International of Gynecologists and Obstetricians) FIGO stages and chemo-resistance. PRPF6 promoted progression, and PTX resistance in vitro and in vivo. And the transcripts of small nucleolar RNA host gene SNHG16-L/S were differentially expressed in OC cells and tissues as detected through real-time PCR (RT-PCR). SNHG16-L/S had opposite effects on progression and PTX resistance in OC. Mechanistically, SNHG16-L inhibited GATA-binding protein 3 (GATA3) transcription by binding to CCAAT/enhancer-binding protein B (CEBPB). Moreover, PRPF6 induced the alternative splicing of SNHG16, causing downregulation of SNHG16-L and, leading to the upregulation of GATA3 expression to further promote metastasis and PTX-resistance in OC. Totally, these data unveiled that PRPF6 promotes metastasis and PTX resistance of OC through SNHG16-L/CEBPB/GATA3 axis, which provides a new direction for OC treatment.

Keywords


Cite This Article

APA Style
WANG, H., ZHOU, Y., ZHANG, S., QI, Y., WANG, M. (2021). PRPF6 promotes metastasis and paclitaxel resistance of ovarian cancer via SNHG16/CEBPB/GATA3 axis. Oncology Research, 29(4), 275-289. https://doi.org/10.32604/or.2022.03561
Vancouver Style
WANG H, ZHOU Y, ZHANG S, QI Y, WANG M. PRPF6 promotes metastasis and paclitaxel resistance of ovarian cancer via SNHG16/CEBPB/GATA3 axis. Oncol Res. 2021;29(4):275-289 https://doi.org/10.32604/or.2022.03561
IEEE Style
H. WANG, Y. ZHOU, S. ZHANG, Y. QI, and M. WANG "PRPF6 promotes metastasis and paclitaxel resistance of ovarian cancer via SNHG16/CEBPB/GATA3 axis," Oncol. Res., vol. 29, no. 4, pp. 275-289. 2021. https://doi.org/10.32604/or.2022.03561



cc This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 1258

    View

  • 654

    Download

  • 0

    Like

Share Link